Schroder Investment Management Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Schroder Investment Management Group’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.7M	Buy	480,504 +98,141	+26%	+$3.65M	0.01%	560
2026 Q1	$13.1M	Buy	382,363 +194,930	+104%	+$8.71M	0.01%	605
2025 Q4	$8.88M	Buy	187,433 +100,115	+115%	+$4.46M	0.01%	659
2025 Q3	$3.8M	Sell	87,318 -53,660	-38%	-$1.72M	﹤0.01%	820
2025 Q2	$4.05M	Buy	140,978 +63,517	+82%	+$1.96M	﹤0.01%	805
2025 Q1	$2.69M	Buy	77,461 +48,100	+164%	+$1.8M	﹤0.01%	870
2024 Q4	$1.49M	Buy	+29,361	New	+$1.64M	﹤0.01%	958

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Schroder Investment Management Group's CRNX Position: Q2 2026 in Review

Schroder Investment Management Group increased its Crinetics Pharmaceuticals (CRNX) stake by 26% in Q2 2026, buying an estimated $3.65M and bringing the position to 480,504 shares worth $17.7M. The position accounts for 0.01% of the portfolio, ranked #560.

Schroder Investment Management Group first reported a position in CRNX in Q4 2024 and has held it in 7 quarters since. 266 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Schroder Investment Management Group held 480,504 shares of Crinetics Pharmaceuticals worth $17.7M as of Q2 2026.
Schroder Investment Management Group bought 98,141 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $3.65M.
Crinetics Pharmaceuticals made up 0.01% of Schroder Investment Management Group's portfolio in Q2 2026, its #560 holding.
Schroder Investment Management Group first reported a position in Crinetics Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
266 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.